Today a key component to infertility treatment with in vitro fertilization (IVF) is controlled ovarian hyper-stimulation (COH), a process whereby supra-physiological amounts of exogenous gonadotropins are administered for the purpose of inducing multi-follicular growth. It is generally accepted that the number of mature oocytes retrieved relates to the number of embryos available for transfer which in turn correlates with the likelihood of treatment success. However, side effects of COH (short and possibly long-term) continue to raise concerns (van Leeuwen et al., 2011) . Robert Edwards, the pioneer of IVF believed that recovery of immature oocytes followed by in vitro maturation (IVM) would be one of the potentially useful treatments for women with infertility (Edwards, 2007a,b) . IVM of immature eggs has emerged as a gonadotropin-independent treatment alternative to conventional IVF (Chian et al., 2004; 2013) . IVM differs from conventional IVF treatment in two major ways. First is the absence of COH and second is the collection of immature oocytes that are cultured in vitro until they reach the metaphase II (mature) stage before IVF is performed.
Since the introduction of IVF and other assisted reproductive technologies (ARTs) for infertility treatment, the health of infants born from these techniques has been a major concern. Individual studies have examined the birth weight and major defects in infants born from IVF or other ART procedures, but with conflicting results (Hansen, 2002; Schieve LA et al., 2002; Rimm et al., 2004; Davies et al., 2012 This is the largest report of infants born from IVM to date. A study is planned to analyse the prevalence of major birth defects in infants conceived following IVM treatment compared to outcomes of this IVM cohort with similar populations of infants conceived by conventional IVF. Based on our preliminary data, IVM does not appear to pose any significantly increased risk of poor obstetric outcomes or congenital abnormalities over those already accepted with IVF or other ARTs. the infants born after IVM (Söderström-Anttila et al., 2006; Buckett et al., 2007; Fadini et al., 2012) . In this paper we describe 1,421 IVM babies born from 1,187 pregnancies from 31 IVF clinics located in 22 countries (Table I) . Data was collected at the time of birth and includes stillbirths but not pregnancy terminations. Information on maternal age, mode of delivery, multiple pregnancy, gestational age at delivery, birth weight, Apgar scores, and congenital abnormality are presented. Congenital malformations were recorded based on the International Statistical Classification of Diseases and Related Health Problems 10th Revision (WHO, 2007) .
The mean maternal age was 34 years. Forty percent (n = 476) infants were delivered vaginally and 60% (n = 711) were delivered by caesarean section. Mean gestational age at delivery and mean birth weight of all infants in singleton, twin, triplet and quadruplet are shown in Table II . Of the 1,421 IVM infants born, there were 18 major congenital abnormalities. It is comparable with the prevalence of major birth defects (MBD) with the spontaneous conception per birth ranged to International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR, 2011). Median Apgar score at 1 min (interquartile range) 9 (7-9) 8 (7-9) 8 (8-9) -
No. of Apgar score at 1 min less than 7 (%)
133 (14) 31 ( LBW: Low birth weight, 1,500-2,500 g; VLBW: Very low birth weight, < 1,500 g; SD: Standard deviation.
